Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Madrigal Pharmaceuticals Inc (MDGL)
NASDAQ:MDGL
RESEARCH TOOLSreports
Madrigal Pharmaceuticals (MDGL) Stock Price & Analysis
1,006 Followers
MDGL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$119.76 - $302.68
Previous Close$220.06
Volume236.44K
Average Volume (3M)517.26K
Market Cap
$4.69B
Enterprise Value$4.57B
Total Cash (Recent Filing)$232.35M
Total Debt (Recent Filing)$116.56M
Price to Earnings (P/E)-9.5
Beta0.85
Next Earnings
Aug 06, 2024EPS Estimate
-$7.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-23.08
Shares Outstanding21,311,526
10 Day Avg. Volume388,452
30 Day Avg. Volume517,264
Standard Deviation0.44
R-Squared0.00167
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)11.42
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-14.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-12.72
Forecast
1Y Price Target
$363.79Price Target Upside65.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Madrigal Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Drug Approval And Market PotentialRezdiffra represents the first FDA-approved treatment for NASH patients with advanced fibrosis, marking a significant market opportunity for Madrigal Pharmaceuticals.
Insurance Coverage And AccessEarly payer coverage decisions for Rezdiffra are favorable, with a considerable percentage of commercial lives already covered, demonstrating progress towards widespread patient access.
Sales And Marketing StrategyMadrigal Pharmaceuticals' effective engagement with top target physicians has resulted in a high prescription rate for Rezdiffra, indicating strong early adoption and trust in the product.
Bears Say
Clinical Trials And Drug ApprovalContinued approval of Rezdiffra is contingent upon verification of clinical benefit in ongoing confirmatory trials, with key results expected in the future.
Drug Coverage And AccessibilitySome drug plans are initially limiting coverage for patients diagnosed via liver biopsy, which could restrict patient access to Rezdiffra.
Drug Pricing And Market CompetitionThe high price tag for Rezdiffra could result in commercial barriers, such as prior authorization at launch and competition from less expensive drugs.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MDGL FAQ
What was Madrigal Pharmaceuticals Inc’s price range in the past 12 months?
Madrigal Pharmaceuticals Inc lowest stock price was $119.76 and its highest was $302.68 in the past 12 months.
What is Madrigal Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Madrigal Pharmaceuticals Inc’s upcoming earnings report date?
Madrigal Pharmaceuticals Inc’s upcoming earnings report date is Aug 06, 2024 which is in 79 days.
How were Madrigal Pharmaceuticals Inc’s earnings last quarter?
Madrigal Pharmaceuticals Inc released its earnings results on May 07, 2024. The company reported -$7.38 earnings per share for the quarter, missing the consensus estimate of -$6.22 by -$1.16.
Is Madrigal Pharmaceuticals Inc overvalued?
According to Wall Street analysts Madrigal Pharmaceuticals Inc’s price is currently Undervalued.
Does Madrigal Pharmaceuticals Inc pay dividends?
Madrigal Pharmaceuticals Inc does not currently pay dividends.
What is Madrigal Pharmaceuticals Inc’s EPS estimate?
Madrigal Pharmaceuticals Inc’s EPS estimate is -$7.49.
How many shares outstanding does Madrigal Pharmaceuticals Inc have?
Madrigal Pharmaceuticals Inc has 21,311,525 shares outstanding.
What happened to Madrigal Pharmaceuticals Inc’s price movement after its last earnings report?
Madrigal Pharmaceuticals Inc reported an EPS of -$7.38 in its last earnings report, missing expectations of -$6.22. Following the earnings report the stock price went down -7.475%.
Which hedge fund is a major shareholder of Madrigal Pharmaceuticals Inc?
Among the largest hedge funds holding Madrigal Pharmaceuticals Inc’s share is Baker Bros Advisors LP. It holds Madrigal Pharmaceuticals Inc’s shares valued at 526M.
---
Madrigal Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$363.79 (65.31% Upside)
$363.79 (65.31% Upside)
Blogger Sentiment
Bullish
MDGL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 8.8%
Last 30 Days ▼ 8.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-20.81%
12-Months-Change
Fundamentals
Return on Equity
-88.78%
Trailing 12-Months
Asset Growth
225.55%
Trailing 12-Months
Company Description
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
---
MDGL Earnings Call
Q1 2024
0:00 / 0:00
---
MDGL Stock 12 Month Forecast
Average Price Target
$363.79
▲(65.31% Upside)
Technical Analysis
Best Analysts Covering MDGL
1 Year
1 Year Success Rate
8/15 ratings generated profit
1 Year Average Return
+113.16%
reiterated a buy rating 2 months ago
Copying Liisa Bayko's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +113.16% per trade.
---